Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.
Anpalakhan S, Signori A, Cortellini A, Verzoni E, Giusti R, Aprile G, Ermacora P, Catino A, Pipitone S, Di Napoli M, Scotti V, Mazzoni F, Guglielmini PF, Veccia A, Maruzzo M, Schinzari G, Casadei C, Grossi F, Rizzo M, Montesarchio V, Verderame F, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Tondini CA, Camerini A, Banzi MC, Sorarù M, Zucali PA, Vignani F, Ricciardi S, Russo A, Cosenza A, Di Maio M, De Giorgi U, Pignata S, Giannarelli D, Pinto C, Buti S, Fornarini G, Rebuzzi SE, Rescigno P, Addeo A, Banna GL, Bersanelli M. Anpalakhan S, et al. Among authors: cosenza a. iScience. 2023 Sep 22;26(11):107970. doi: 10.1016/j.isci.2023.107970. eCollection 2023 Nov 17. iScience. 2023. PMID: 37860695 Free PMC article.
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G, Minari R, Zecca A, Cavazzoni A, Ferri V, Mori C, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Missale G, Petronini PG, Quaini F, Tiseo M. Mazzaschi G, et al. Among authors: cosenza a. Lung Cancer. 2020 Oct;148:1-11. doi: 10.1016/j.lungcan.2020.07.028. Epub 2020 Aug 2. Lung Cancer. 2020. PMID: 32768804
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R, Bonatti F, Mazzaschi G, Dodi A, Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Quaini F, Ardizzoni A, Tiseo M. Minari R, et al. Among authors: cosenza a. Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18. Tumori. 2022. PMID: 34002648
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Bersanelli M, Cortellini A, Leonetti A, Parisi A, Tiseo M, Bordi P, Michiara M, Bui S, Cosenza A, Ferri L, Giudice GC, Testi I, Rapacchi E, Camisa R, Vincenzi B, Caruso G, Rauti AN, Arturi F, Tucci M, Santo V, Ricozzi V, Burtet V, Sgargi P, Todeschini R, Zustovich F, Stucci LS, Santini D, Buti S. Bersanelli M, et al. Among authors: cosenza a. Cancer Immunol Immunother. 2023 Nov;72(11):3707-3716. doi: 10.1007/s00262-023-03522-3. Epub 2023 Aug 28. Cancer Immunol Immunother. 2023. PMID: 37638980 Free PMC article.
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Verzè M, Minari R, Gnetti L, Bordi P, Leonetti A, Cosenza A, Ferri L, Majori M, De Filippo M, Buti S, Gasparro D, Nizzoli R, Azzoni C, Bottarelli L, Squadrilli A, Mozzoni P, Tiseo M. Verzè M, et al. Among authors: cosenza a. Cancers (Basel). 2021 Oct 28;13(21):5403. doi: 10.3390/cancers13215403. Cancers (Basel). 2021. PMID: 34771566 Free PMC article.
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
Leonetti A, Verzè M, Minari R, Perrone F, Gnetti L, Bordi P, Pluchino M, Nizzoli R, Azzoni C, Bottarelli L, Lagrasta CAM, Mazzaschi G, Buti S, Gasparro D, Cosenza A, Ferri L, Majori M, De Filippo M, Ampollini L, La Monica S, Alfieri R, Silini EM, Tiseo M. Leonetti A, et al. Among authors: cosenza a. Br J Cancer. 2024 Jan;130(1):135-142. doi: 10.1038/s41416-023-02475-9. Epub 2023 Nov 8. Br J Cancer. 2024. PMID: 37938348
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M. Bordi P, et al. Among authors: cosenza a. Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19. Lung Cancer. 2019. PMID: 31027702 Clinical Trial.
128 results